158 related articles for article (PubMed ID: 18474007)
1. Selective internal radiation therapy with Yttrium-90 for unresectable liver tumours.
Khodjibekova M; Szyszko T; Khan S; Nijran K; Tait P; Al-Nahhas A
Rev Recent Clin Trials; 2007 Sep; 2(3):212-6. PubMed ID: 18474007
[TBL] [Abstract][Full Text] [Related]
2. Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma.
Welsh JS; Kennedy AS; Thomadsen B
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S62-73. PubMed ID: 16979443
[TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial yttrium 90 microspheres: another treatment option for hepatocellular carcinoma.
Dawson LA
J Vasc Interv Radiol; 2005 Feb; 16(2 Pt 1):161-4. PubMed ID: 15713916
[No Abstract] [Full Text] [Related]
4. Clinical care and technical recommendations for 90yttrium microsphere treatment of liver cancer.
Wang SC; Bester L; Burnes JP; Clouston JE; Hugh TJ; Little AF; Padbury RT; Price D
J Med Imaging Radiat Oncol; 2010 Jun; 54(3):178-87. PubMed ID: 20598004
[TBL] [Abstract][Full Text] [Related]
5. Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease.
Turkmen C; Ucar A; Poyanli A; Vatankulu B; Ozkan G; Basaran M; Serin K; Sanli Y; Adalet I
Cancer Biother Radiopharm; 2013 Sep; 28(7):534-40. PubMed ID: 23647219
[TBL] [Abstract][Full Text] [Related]
6. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres.
Lau WY; Kennedy AS; Kim YH; Lai HK; Lee RC; Leung TW; Liu CS; Salem R; Sangro B; Shuter B; Wang SC
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):401-7. PubMed ID: 20950954
[TBL] [Abstract][Full Text] [Related]
7. Concordant F-18 FDG PET and Y-90 Bremsstrahlung scans depict selective delivery of Y-90-microspheres to liver tumors: confirmation with histopathology.
Tehranipour N; AL-Nahhas A; Canelo R; Stamp G; Woo K; Tait P; Gishen P
Clin Nucl Med; 2007 May; 32(5):371-4. PubMed ID: 17452865
[TBL] [Abstract][Full Text] [Related]
8. Treatment response in liver metastases following 90Y SIR-spheres: an evaluation with PET.
Lin M; Shon IH; Wilson R; D'Amours SK; Schlaphoff G; Lin P
Hepatogastroenterology; 2007; 54(75):910-2. PubMed ID: 17591090
[TBL] [Abstract][Full Text] [Related]
9. Yttrium-90 microspheres (TheraSphere and SIR-Spheres) for the treatment of unresectable hepatocellular carcinoma.
Allison C
Issues Emerg Health Technol; 2007 Sep; (102):1-6. PubMed ID: 17824141
[TBL] [Abstract][Full Text] [Related]
10. Complete eradication of hepatic metastasis from colorectal cancer by Yttrium-90 SIRT.
Garrean S; Muhs A; Bui JT; Blend MJ; Owens C; Helton WS; Espat NJ
World J Gastroenterol; 2007 Jun; 13(21):3016-9. PubMed ID: 17589957
[TBL] [Abstract][Full Text] [Related]
11. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors.
Kucuk ON; Soydal C; Lacin S; Ozkan E; Bilgic S
World J Surg Oncol; 2011 Aug; 9():86. PubMed ID: 21819613
[TBL] [Abstract][Full Text] [Related]
12. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours.
Jiao LR; Szyszko T; Al-Nahhas A; Tait P; Canelo R; Stamp G; Wasan H; Lowdell C; Philips R; Thillainayagam A; Bansi D; Rubello D; Limongelli P; Woo K; Habib NA
Eur J Surg Oncol; 2007 Jun; 33(5):597-602. PubMed ID: 17433608
[TBL] [Abstract][Full Text] [Related]
13. Selective internal radiation therapy (SIRT) with yttrium-90 microspheres for unresectable intrahepatic cholangiocarcinoma.
Abeysinghe V; Sundararajan S; Delriviere L; Tibballs J
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29523614
[TBL] [Abstract][Full Text] [Related]
14. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.
Szyszko T; Al-Nahhas A; Canelo R; Habib N; Jiao L; Wasan H; Pagou M; Tait P
Nucl Med Commun; 2007 Jan; 28(1):15-20. PubMed ID: 17159544
[TBL] [Abstract][Full Text] [Related]
15. Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors.
Sarfaraz M; Kennedy AS; Cao ZJ; Sackett GD; Yu CX; Lodge MA; Murthy R; Line BR; Van Echo DA
Med Phys; 2003 Feb; 30(2):199-203. PubMed ID: 12607837
[TBL] [Abstract][Full Text] [Related]
16. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities.
Goin JE; Salem R; Carr BI; Dancey JE; Soulen MC; Geschwind JF; Goin K; Van Buskirk M; Thurston K
J Vasc Interv Radiol; 2005 Feb; 16(2 Pt 1):205-13. PubMed ID: 15713921
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
[TBL] [Abstract][Full Text] [Related]
18. An experimental study and clinical pilot trials on yttrium-90 glass microspheres through the hepatic artery for treatment of primary liver cancer.
Yan ZP; Lin G; Zhao HY; Dong YH
Cancer; 1993 Dec; 72(11):3210-5. PubMed ID: 8242543
[TBL] [Abstract][Full Text] [Related]
19. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up.
Andrews JC; Walker SC; Ackermann RJ; Cotton LA; Ensminger WD; Shapiro B
J Nucl Med; 1994 Oct; 35(10):1637-44. PubMed ID: 7931662
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
